Sarepta Therapeutics has paused shipments of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys for non-ambulatory patients following a second death attributed to acute liver failure. Both fatalities involved patients whose disease had progressed to wheelchair dependence, with the first death occurring earlier this year in a 16-year-old. Sarepta is collaborating with experts on an enhanced immunosuppressive regimen to mitigate liver toxicity and is consulting the FDA before implementing changes. Shipments to ambulatory patients continue, with ongoing corticosteroid pre- and post-infusion protocols.